International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

LEARN MORE

Nimodipine Compounded Oral Suspension: A True Documented Medical Need

Author(s): McElhiney Linda F

Issue: Mar/Apr 2019 - Volume 23, Number 2
View All Articles in Issue

Page(s): 106-111

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 1

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 2

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 3

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 4

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 5

Nimodipine Compounded Oral Suspension: A True Documented Medical Need Page 6

Download in electronic PDF format for $75

Abstract: What happens when there is an entire patient population, not just a specific patient, which cannot take a commercial product due to significant adverse effects, although the commercial product has a U.S. Food and Drug Administration-approved indication for the medical problem? What should or can be done in this situation? This article discusses this dilemma using a subarachnoid hemorrhage as an example of a true documented medical need, and discusses the option and circumstances surrounding the compounding of a nimodipine oral solution, a U.S. Food and Drug Administration–approved indication for the treatment of subarachnoid hemorrhages.

Related Keywords: nimodipine, dihydropyridine calcium channel blocker, formulations, US Food and Drug Administration, FDA, DQSA, subarachnoid hemorrhage, bleeding in brain, drug safety, dosage forms, adverse effects

Related Categories: FORMULATIONS, LEGAL, ADVERSE DRUG EVENTS, HEMOSTASIS, BLEEDING, ANTICOAGULATION, NEUROLOGY

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
Nimodipine Compounded Oral Suspension: A True Documented Medical Need McElhiney Linda F	Mar/Apr 2019 Pg. 106-111
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Preventing Medication Errors with Nimodipine by Compounding Proper Dosage Forms McElhiney Linda F	Sep/Oct 2013 Pg. 364-368
Nimodipine 30-mg Capsules Allen Loyd V Jr	Jan/Feb 2014 Pg. 65
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms Akers Michael J	Jan/Feb 2017 Pg. 47-56
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
Nimodipine 3-mg/mL Oral Solution Allen Loyd V Jr	Sep/Oct 2015 Pg. 407
Formulation Development of Modafinil Sprinkle Dosage Form: Study on the Effect of Food on Dosage Kumaravelrajan Rajagopal, Karthik B, Venkatasan Suba	Nov/Dec 2022 Pg. 516-521
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients Allen Loyd V Jr	Nov/Dec 2023 Pg. 474-481
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Allen W Chris, Greeson Nicole MH, Mixon William	Nov/Dec 2020 Pg. 451-458
Return to Top